Short Interest in Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) Declines By 33.4%

Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) was the recipient of a large decrease in short interest during the month of July. As of July 15th, there was short interest totaling 8,407 shares, a decrease of 33.4% from the June 30th total of 12,617 shares. Currently, 4.2% of the shares of the stock are sold short. Based on an average trading volume of 2,362 shares, the short-interest ratio is currently 3.6 days.

Amplify Weight Loss Drug & Treatment ETF Stock Performance

NYSEARCA:THNR traded down $0.46 during mid-day trading on Friday, hitting $25.40. 1,659 shares of the company’s stock traded hands, compared to its average volume of 2,058. The company has a market cap of $5.08 million, a PE ratio of 24.31 and a beta of 0.37. The firm’s 50 day simple moving average is $25.17 and its 200 day simple moving average is $25.16. Amplify Weight Loss Drug & Treatment ETF has a 1 year low of $21.70 and a 1 year high of $27.28.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Amplify Weight Loss Drug & Treatment ETF stock. Cravens & Co Advisors LLC acquired a new position in shares of Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) in the 4th quarter, according to its most recent 13F filing with the SEC. The fund acquired 15,023 shares of the company’s stock, valued at approximately $390,000. Cravens & Co Advisors LLC owned about 10.02% of Amplify Weight Loss Drug & Treatment ETF at the end of the most recent reporting period.

About Amplify Weight Loss Drug & Treatment ETF

The Amplify Weight Loss Drug & Treatment ETF (THNR) is an exchange-traded fund that is based on the VettaFi Weight Loss Drug index. The fund tracks a modified market cap-weighted index of companies from developed markets that manufacture and enable GLP-1 agonist pharmaceutical businesses. THNR was launched on May 21, 2024 and is issued by Amplify Investments.